Personal Health  
comments_image Comments

Media Trumpet Dangerous Heart Drug

Crestor has been named one of the top five most dangerous drugs by the FDA. Yet it's being sold as immortality in a bottle.
 
 
Share
 
 
 
 

When Dr. Paul Ridker of Brigham and Women's Hospital in Boston presented the results of the AstraZeneca-funded JUPITER study at the American Heart Association conference in November, there were a lot more stenographers than skeptics in the press corps.  (JUPITER standing for Justification for the Use of Statins in Primary Prevention.)

How could a drug-company-funded study designed to show why the general population should use its drug (Crestor, or rosuvastatin) be objective? Or even newsworthy? Especially when its lead author is co-inventor on the related patent? And its authors list 131 financial ties to drug companies? Hello? 

But the media didn't let overt conflicts of interest -- COIs as pharma calls them, because they're so common -- ruin the story. 

"AstraZeneca's Crestor Cuts Death, Heart Attack," exalted Reuters, remembering the PR dictum of getting name and company in the headline. "Crestor Study Seen Changing Preventive Treatment!" 

"Wider Cholesterol Drug Use May Save Lives," trumpeted other headlines. "Statins for Everyone!"  "Crestor in the Water?" 

Was this the same Crestor that was vilified in a Lancet editorial three months after its 2003 U.S. approval as "inadequately investigated?" The one named one of the top five most dangerous drugs by the FDA's Dr. David "Vioxx" Graham on Capitol Hill in 2004? Petitioned for recall by the Washington-based Public Citizen?  Found worthless against chronic heart failure just one month earlier in Lancet?  

In the feeding frenzy to cover the self-engineered drug breakthrough, where was media mention of another American Heart Association finding about Crestor in its journal Circulation in 2005? The one that said Crestor "was significantly more likely to be associated with the composite end point of rhabdomyolysis, proteinuria, nephropathy or renal failure," than other drugs? 

Where was mention of the FDA warning about rhabdomyolysis -- the muscle disease that did in Bayer's Baycol -- that was added to Crestor in 2005 after a patient death -- along with warnings to physicians about Crestor use in Asian patients, people with severe kidney disease and patients taking cyclosporine?  

Oops. 

But while the gee-whiz press focused on the JUPITER study's startling results -- the Crestor group had a 54 percent reduction in heart attacks, 48 percent reduction in strokes and 20 percent reduction in death compared to placebo -- especially in light of the fact that the study group was free of heart disease and high cholesterol, most doctors wouldn't drink the AstraZeneca Kool-Aid. 

The study's 17,802 enrollees may have had normal levels of the bad LDL cholesterol, but some were "walking vasculopaths," with abnormal C-reactive protein levels [CRP] which indicate inflammation in the body said Dr. Bernadine Healy, health editor for U.S. News & World Report. 

"As a result, the JUPITER trial was riddled with obesity, high blood pressure, pre-diabetes and genes predisposing to heart disease," said Healy. "Almost 3,000 enrollees were smokers, a big-time CRP elevator, and only 10 percent took aspirin, an inexpensive preventive medicine that protects against both heart disease and stroke. (Aspirin also lowers CRP.) Other study patients were really healthy, free of any known risk factors, and yet had elevated CRP for no obvious reason." 

While the press bought AstraZeneca's contrivance that the JUPITER study was so conclusive it was ended early, many of the 470 doctors who posted online comments after the study in the New England Journal of Medicine (Nov. 20, 2008) said you ended the trial when

"It is well established that RCTs [randomized controlled trials] stopped early overestimate benefits significantly," wrote a physician from Rochester, Minn. 

"It is shocking that this trial was terminated 50 percent through, based on a small, absolute benefit, with real questions about long-term risk," said a poster from the Public Health Law Program, LSU Law Center. 

 
See more stories tagged with: